Patient Access and Business Considerations in Medical Cannabis
Patient access is an important part of the medicinal cannabis sector. Healthcare providers, clinics, manufacturers and distributors may all contribute to the process through which patients receive information, clinical assessments, prescriptions and prescribed products.
Medicinal Organic Cannabis Australia (MOCA) has been described in company material as providing telehealth-related services. However, claims about its patient numbers, geographic operations, revenue, market position and commercial performance require independent verification. A growing patient base should not be assumed without reliable supporting data.
Patient Numbers and Business Performance
For a medicinal cannabis business, patient activity may influence demand for consultations and prescribed products. However, patient numbers alone do not establish profitability or investment value.
Investors assessing a healthcare business should consider:
Verified patient numbers and changes over time.
Consultation volumes and practitioner availability.
Revenue per patient and operating costs.
Patient retention and the reasons for discontinuing care.
Regulatory requirements and the costs of maintaining compliant services.
Financial statements, cash flow and funding requirements.
Repeat consultations or ongoing treatment may contribute to business revenue, but continuity of care should be determined by clinical need rather than commercial objectives.
Telehealth and Patient Access
Telehealth can provide remote consultations and follow-up appointments, potentially reducing travel requirements for some patients. Its availability depends on practitioner registration, clinical suitability and applicable laws.
MOCA's booking website and its published information on People, Planet and Profit provide company-related information. These sources should not be treated as independent confirmation of patient growth, commercial performance or investment returns.
Organic Products and Evidence
Businesses that describe their medicinal cannabis products as organic should provide evidence of their cultivation methods and any relevant certification. Organic claims alone do not establish clinical effectiveness, product safety or a commercial advantage.
Investment Risks
Medicinal cannabis investments can be affected by regulatory changes, competition, product supply, clinical evidence, operating costs and financing requirements. Investors should review independently verified company information and assess the risks before making decisions.
A patient-centred healthcare model should prioritise appropriate clinical assessment, informed consent, patient privacy and ongoing medical supervision. Prospective investors should conduct independent due diligence and obtain qualified financial advice.
How to Access a Medicinal Cannabis Prescription in Australia
Patients considering medicinal cannabis in Australia should begin by discussing their circumstances with a qualified healthcare professional. Access depends on clinical suitability, the product being considered and the applicable regulatory pathway.
Step 1: Consult a Healthcare Professional
A patient can discuss their symptoms, medical history, current medicines and previous treatments with a registered medical practitioner. The practitioner assesses whether medicinal cannabis may be an appropriate option.
Step 2: Review Treatment Suitability
The practitioner considers the available clinical evidence, potential benefits, risks, side effects and possible interactions with other medicines. Medicinal cannabis is not suitable for everyone, and a consultation does not guarantee a prescription.
Step 3: Determine the Applicable Access Pathway
Some medicinal cannabis products are not included in the Australian Register of Therapeutic Goods (ARTG). Depending on the product and circumstances, access may involve the Therapeutic Goods Administration's (TGA) Special Access Scheme or Authorised Prescriber arrangements.
Other products may be available through different regulatory arrangements, including registered products or approved clinical trials.
The practitioner determines which requirements apply and completes any necessary regulatory steps.
Step 4: Prescription and Dispensing
If treatment is considered appropriate and the relevant requirements are met, the practitioner can issue a prescription. The patient can then obtain the prescribed product through a pharmacy or other lawful dispensing arrangement.
The pharmacist can explain the product, directions for use, storage requirements and potential side effects.
Step 5: Follow-up and Monitoring
Ongoing medical supervision is important. Follow-up appointments allow the practitioner to assess treatment response, review adverse effects and determine whether the treatment should continue or change.
For additional background, see How to Obtain Your Medical Prescription in Australia.
Patients should confirm current requirements with their healthcare professional and the relevant authorities, as access arrangements can vary according to the product and jurisdiction.
An Overview of Medicinal Cannabis in Australia
Medicinal cannabis is used in Australia under a regulated framework that governs access, prescribing, supply and product quality. It includes products containing cannabinoids such as cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC), which have different properties and potential effects.
Regulatory Framework
The Therapeutic Goods Administration (TGA) oversees the regulation of therapeutic goods, including relevant medicinal cannabis products and access arrangements.
Some medicinal cannabis products are included in the Australian Register of Therapeutic Goods (ARTG), while others are unapproved therapeutic goods that may be accessed through applicable pathways such as the Special Access Scheme or Authorised Prescriber arrangements.
Federal requirements operate alongside relevant state and territory laws. Rules may apply to prescribing, dispensing, possession and use.
Medical Uses and Evidence
Medicinal cannabis may be considered by healthcare professionals for certain patients and circumstances. Research has examined its use in areas including:
Certain forms of treatment-resistant epilepsy.
Some symptoms associated with multiple sclerosis.
Particular types of chronic pain.
Chemotherapy-related nausea and vomiting.
Symptoms in some palliative care settings.
The strength of evidence differs between conditions and products. Evidence supporting one cannabinoid or formulation should not automatically be applied to another. Medicinal cannabis should be considered through an individual clinical assessment rather than assumed to be an appropriate treatment for a particular diagnosis.
Accessing Medicinal Cannabis
Patients generally need to consult a qualified healthcare professional who can assess their medical circumstances and determine whether treatment is appropriate.
Depending on the product, the practitioner may need to use an applicable TGA access pathway. If treatment is approved or otherwise permitted under the relevant arrangements, a prescription can be issued and dispensed through a lawful supply channel.
Follow-up care is important to review effectiveness, side effects and any changes in the patient's health or medication.
Patient Safety
Cannabis-based medicines can cause adverse effects and may interact with other medicines. Products containing THC may impair attention, coordination and driving ability. Patients should follow their prescriber's instructions and discuss any concerns before changing or stopping treatment.
Further Information
For additional background, see An Overview of Medical Cannabis in Australia.
Patients and healthcare professionals should consult current TGA guidance and applicable state or territory requirements. Regulatory arrangements can change, and access to medicinal cannabis does not guarantee a particular therapeutic outcome.